For the first time ever, the National Cancer Institute is funding a study that will look into psilocybin's effect on the emotional and mental suffering of terminal cancer patients. Led by Associate Professor of Internal Medicine Stacy Fischer and Clinical Health Psychology Professor Jim Grigsby, the study will monitor patients who undergo extensive sessions of psychotherapy, during which each participant will receive 25 milligrams of psilocybin. The relatively new therapeutic practice is part of palliative care, which treats terminally ill patients' mental and physical needs. If the trial is promising, Fischer and Grigsby hope to see more government permitted research into medical psychedelics like psilocybin and MDMA.
CU to Study How Psilocybin Affects Mental Health of Cancer Patients
Westword, March 10